APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Checkpoint Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immune Checkpoint Agents Market Outlook and Growth Opportunities 2026

26 December 2025199 pages

Choose your research edition.

Industry ResearchImmune Checkpoint Agents Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Checkpoint Agents Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Immune Checkpoint Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Checkpoint Agents Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Checkpoint Agents Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Immune Checkpoint Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immune Checkpoint Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immune Checkpoint Agents market include Bristol Myers Squibb, AstraZeneca, Roche and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Immune Checkpoint Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immune Checkpoint Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immune Checkpoint Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Immune Checkpoint Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Immune Checkpoint Agents Segment by Company

Bristol Myers Squibb

AstraZeneca

Roche

Merck

Immune Checkpoint Agents Segment by Type

Anti-PD-L1 Drug

Anti-PD-1 Drug

CTLA4

Immune Checkpoint Agents Segment by Application

Lung Cancer

Melanoma

Colorectal Cancer

Prostate Cancer

BreastCancer

Blood Cancers

Immune Checkpoint Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immune Checkpoint Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Immune Checkpoint Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immune Checkpoint Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Immune Checkpoint Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Immune Checkpoint Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immune Checkpoint Agents industry.

Chapter 3: Detailed analysis of Immune Checkpoint Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Immune Checkpoint Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Immune Checkpoint Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immune Checkpoint Agents Industry Trends Table 2. Immune Checkpoint Agents Industry Drivers Table 3. Immune Checkpoint Agents Industry Opportunities and Challenges Table 4. Immune Checkpoint Agents Industry Restraints Table 5. Global Immune Checkpoint Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immune Checkpoint Agents Revenue Share by Company (2021-2026) Table 7. Global Immune Checkpoint Agents Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Immune Checkpoint Agents Sales Volume Share by Company (2021-2026) Table 9. Global Immune Checkpoint Agents Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Immune Checkpoint Agents Company Ranking, (2024-2026) & (USD Million) Table 11. Global Immune Checkpoint Agents Key Company Manufacturing Base & Headquarters Table 12. Global Immune Checkpoint Agents Company, Product Type & Application Table 13. Global Immune Checkpoint Agents Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Immune Checkpoint Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Anti-PD-L1 Drug Table 18. Significant Companies of Anti-PD-1 Drug Table 19. Significant Companies of CTLA4 Table 20. Global Immune Checkpoint Agents Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Immune Checkpoint Agents Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Immune Checkpoint Agents Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Immune Checkpoint Agents Sales Volume Share by Type (2021-2026) Table 24. Global Immune Checkpoint Agents Sales Volume Share by Type (2027-2032) Table 25. Global Immune Checkpoint Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Immune Checkpoint Agents Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Immune Checkpoint Agents Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Immune Checkpoint Agents Sales Value Share by Type (2021-2026) Table 29. Global Immune Checkpoint Agents Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Lung Cancer Table 31. Significant Companies of Melanoma Table 32. Significant Companies of Colorectal Cancer Table 33. Significant Companies of Prostate Cancer Table 34. Significant Companies of BreastCancer Table 35. Significant Companies of Blood Cancers Table 36. Global Immune Checkpoint Agents Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Immune Checkpoint Agents Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Immune Checkpoint Agents Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Immune Checkpoint Agents Sales Volume Share by Application (2021-2026) Table 40. Global Immune Checkpoint Agents Sales Volume Share by Application (2027-2032) Table 41. Global Immune Checkpoint Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Immune Checkpoint Agents Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Immune Checkpoint Agents Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Immune Checkpoint Agents Sales Value Share by Application (2021-2026) Table 45. Global Immune Checkpoint Agents Sales Value Share by Application (2027-2032) Table 46. Global Immune Checkpoint Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Immune Checkpoint Agents Sales by Region (2021-2026) & (K Units) Table 48. Global Immune Checkpoint Agents Sales Market Share by Region (2021-2026) Table 49. Global Immune Checkpoint Agents Sales by Region (2027-2032) & (K Units) Table 50. Global Immune Checkpoint Agents Sales Market Share by Region (2027-2032) Table 51. Global Immune Checkpoint Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Immune Checkpoint Agents Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Immune Checkpoint Agents Sales Value Share by Region (2021-2026) Table 54. Global Immune Checkpoint Agents Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Immune Checkpoint Agents Sales Value Share by Region (2027-2032) Table 56. Global Immune Checkpoint Agents Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Immune Checkpoint Agents Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Immune Checkpoint Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 61. Global Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 62. Global Immune Checkpoint Agents Sales by Country (2027-2032) & (K Units) Table 63. Global Immune Checkpoint Agents Sales Market Share by Country (2027-2032) Table 64. Global Immune Checkpoint Agents Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Immune Checkpoint Agents Sales Value Market Share by Country (2021-2026) Table 66. Global Immune Checkpoint Agents Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Immune Checkpoint Agents Sales Value Market Share by Country (2027-2032) Table 68. Bristol Myers Squibb Company Information Table 69. Bristol Myers Squibb Business Overview Table 70. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio Table 72. Bristol Myers Squibb Recent Development Table 73. AstraZeneca Company Information Table 74. AstraZeneca Business Overview Table 75. AstraZeneca Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. AstraZeneca Immune Checkpoint Agents Product Portfolio Table 77. AstraZeneca Recent Development Table 78. Roche Company Information Table 79. Roche Business Overview Table 80. Roche Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Roche Immune Checkpoint Agents Product Portfolio Table 82. Roche Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Merck Immune Checkpoint Agents Product Portfolio Table 87. Merck Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Immune Checkpoint Agents Distributors List Table 91. Immune Checkpoint Agents Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Immune Checkpoint Agents Product Image Figure 2. Global Immune Checkpoint Agents Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 4. Global Immune Checkpoint Agents Sales (2021-2032) & (K Units) Figure 5. Global Immune Checkpoint Agents Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Immune Checkpoint Agents Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Anti-PD-L1 Drug Image Figure 10. Anti-PD-1 Drug Image Figure 11. CTLA4 Image Figure 12. Global Immune Checkpoint Agents Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Immune Checkpoint Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Immune Checkpoint Agents Sales Volume Share by Type (2021-2032) Figure 15. Global Immune Checkpoint Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Immune Checkpoint Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Immune Checkpoint Agents Sales Value Share by Type (2021-2032) Figure 18. Lung Cancer Image Figure 19. Melanoma Image Figure 20. Colorectal Cancer Image Figure 21. Prostate Cancer Image Figure 22. BreastCancer Image Figure 23. Blood Cancers Image Figure 24. Global Immune Checkpoint Agents Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Immune Checkpoint Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Immune Checkpoint Agents Sales Volume Share by Application (2021-2032) Figure 27. Global Immune Checkpoint Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Immune Checkpoint Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Immune Checkpoint Agents Sales Value Share by Application (2021-2032) Figure 30. Global Immune Checkpoint Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Immune Checkpoint Agents Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Immune Checkpoint Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Immune Checkpoint Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 35. North America Immune Checkpoint Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Immune Checkpoint Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Immune Checkpoint Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 41. South America Immune Checkpoint Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Immune Checkpoint Agents Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Immune Checkpoint Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Immune Checkpoint Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Immune Checkpoint Agents Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Immune Checkpoint Agents Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Applications
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Prostate Cancer
  • BreastCancer
  • Blood Cancers
Companies covered
  • Bristol Myers Squibb
  • AstraZeneca
  • Roche
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Immune Checkpoint Agents Sales Value (2021-2032)
  4. 1.2.2 Global Immune Checkpoint Agents Sales Volume (2021-2032)
  5. 1.2.3 Global Immune Checkpoint Agents Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Immune Checkpoint Agents Market Dynamics
  1. 2.1 Immune Checkpoint Agents Industry Trends
  2. 2.2 Immune Checkpoint Agents Industry Drivers
  3. 2.3 Immune Checkpoint Agents Industry Opportunities and Challenges
  4. 2.4 Immune Checkpoint Agents Industry Restraints
3 Immune Checkpoint Agents Market by Company
  1. 3.1 Global Immune Checkpoint Agents Company Revenue Ranking in 2025
  2. 3.2 Global Immune Checkpoint Agents Revenue by Company (2021-2026)
  3. 3.3 Global Immune Checkpoint Agents Sales Volume by Company (2021-2026)
  4. 3.4 Global Immune Checkpoint Agents Average Price by Company (2021-2026)
  5. 3.5 Global Immune Checkpoint Agents Company Ranking (2024-2026)
  6. 3.6 Global Immune Checkpoint Agents Company Manufacturing Base and Headquarters
  7. 3.7 Global Immune Checkpoint Agents Company Product Type and Application
  8. 3.8 Global Immune Checkpoint Agents Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Immune Checkpoint Agents Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Immune Checkpoint Agents Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Immune Checkpoint Agents Market by Type
  1. 4.1 Immune Checkpoint Agents Type Introduction
  2. 4.1.1 Anti-PD-L1 Drug
  3. 4.1.2 Anti-PD-1 Drug
  4. 4.1.3 CTLA4
  5. 4.2 Global Immune Checkpoint Agents Sales Volume by Type
  6. 4.2.1 Global Immune Checkpoint Agents Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Immune Checkpoint Agents Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Immune Checkpoint Agents Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Immune Checkpoint Agents Sales Value by Type
  10. 4.3.1 Global Immune Checkpoint Agents Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Immune Checkpoint Agents Sales Value by Type (2021-2032)
  12. 4.3.3 Global Immune Checkpoint Agents Sales Value Share by Type (2021-2032)
5 Immune Checkpoint Agents Market by Application
  1. 5.1 Immune Checkpoint Agents Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Melanoma
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 BreastCancer
  7. 5.1.6 Blood Cancers
  8. 5.2 Global Immune Checkpoint Agents Sales Volume by Application
  9. 5.2.1 Global Immune Checkpoint Agents Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Immune Checkpoint Agents Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Immune Checkpoint Agents Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Immune Checkpoint Agents Sales Value by Application
  13. 5.3.1 Global Immune Checkpoint Agents Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Immune Checkpoint Agents Sales Value by Application (2021-2032)
  15. 5.3.3 Global Immune Checkpoint Agents Sales Value Share by Application (2021-2032)
6 Immune Checkpoint Agents Regional Sales and Value Analysis
  1. 6.1 Global Immune Checkpoint Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immune Checkpoint Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Immune Checkpoint Agents Sales by Region: 2021-2026
  4. 6.2.2 Global Immune Checkpoint Agents Sales by Region (2027-2032)
  5. 6.3 Global Immune Checkpoint Agents Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Immune Checkpoint Agents Sales Value by Region (2021-2032)
  7. 6.4.1 Global Immune Checkpoint Agents Sales Value by Region: 2021-2026
  8. 6.4.2 Global Immune Checkpoint Agents Sales Value by Region (2027-2032)
  9. 6.5 Global Immune Checkpoint Agents Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Immune Checkpoint Agents Sales Value (2021-2032)
  12. 6.6.2 North America Immune Checkpoint Agents Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Immune Checkpoint Agents Sales Value (2021-2032)
  15. 6.7.2 Europe Immune Checkpoint Agents Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Immune Checkpoint Agents Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Immune Checkpoint Agents Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Immune Checkpoint Agents Sales Value (2021-2032)
  21. 6.9.2 South America Immune Checkpoint Agents Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Immune Checkpoint Agents Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Immune Checkpoint Agents Sales Value Share by Country, 2025 VS 2032
7 Immune Checkpoint Agents Country-level Sales and Value Analysis
  1. 7.1 Global Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immune Checkpoint Agents Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Immune Checkpoint Agents Sales by Country (2021-2032)
  4. 7.3.1 Global Immune Checkpoint Agents Sales by Country (2021-2026)
  5. 7.3.2 Global Immune Checkpoint Agents Sales by Country (2027-2032)
  6. 7.4 Global Immune Checkpoint Agents Sales Value by Country (2021-2032)
  7. 7.4.1 Global Immune Checkpoint Agents Sales Value by Country (2021-2026)
  8. 7.4.2 Global Immune Checkpoint Agents Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Immune Checkpoint Agents Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Immune Checkpoint Agents Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Immune Checkpoint Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Immune Checkpoint Agents Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Immune Checkpoint Agents Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Immune Checkpoint Agents Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Immune Checkpoint Agents Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Immune Checkpoint Agents Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Immune Checkpoint Agents Product Portfolio
  24. 8.4.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Immune Checkpoint Agents Value Chain Analysis
  2. 9.1.1 Immune Checkpoint Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Immune Checkpoint Agents Sales Mode & Process
  6. 9.2 Immune Checkpoint Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Immune Checkpoint Agents Distributors
  9. 9.2.3 Immune Checkpoint Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst